The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer.
The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer.
复制标题
癌症中 microRNA 与 Wnt/β-catenin 信号通路之间的串扰
DOI：
10.18632/oncotarget.12923
复制
发表时间：
2017-02-21
期刊：
影响因子：
--
通讯作者：
Jin Z
中科院分区：
文献类型：
--
作者：
Peng Y;Zhang X;Feng X;Fan X;Jin Z
越来越多的证据表明，microRNA（miR）的失调和Wnt/β-catenin信号通路共同驱动癌的发生，癌症转移和耐药性。现就miR与Wnt/β-catenin信号通路的相互作用在肿瘤发生发展中的作用作一综述。发现miR在各个步骤激活或抑制经典Wnt途径。另一方面，Wnt激活通过直接结合其启动子并激活转录来增加miR的表达。此外，一些miR与Wnt/β-catenin信号通路之间存在相互反馈环。基于miR的治疗剂的临床试验被研究用于实体瘤和血液肿瘤，然而，在最终临床应用之前必须克服关于低生物利用度和可能的副作用的挑战。这篇综述将描述目前对Wnt/β-catenin信号级联的miR串扰的理解。更好地了解调控网络将为基于miR的治疗开发提供深入了解。
Mounting evidence has indicated microRNA (miR) dysregulation and the Wnt/β-catenin signaling pathway jointly drive carcinogenesis, cancer metastasis, and drug-resistance. The current review will focus on the role of the crosstalk between miRs and the Wnt/β-catenin signaling pathway in cancer development. MiRs were found to activate or inhibit the canonical Wnt pathway at various steps. On the other hand, Wnt activation increases expression of miR by directly binding to its promoter and activating transcription. Moreover, there are mutual feedback loops between some miRs and the Wnt/β-catenin signaling pathway. Clinical trials of miR-based therapeutic agents are investigated for solid and hematological tumors, however, challenges concerning low bioavailability and possible side effects must be overcome before the final clinical application. This review will describe current understanding of miR crosstalk with the Wnt/β-catenin signaling cascade. Better understanding of the regulatory network will provide insight into miR-based therapeutic development.